take a look at these reports and see if there is anyway a credible analyst would drop coverage http://www.pluristem.com/national%20report10-1-11.pdf http://www.pluristem.com/National%20February%203%202011.pdf now they do not have a financing overhang. This will be one of the premier stem cell companies. this is a good analysis. Someone must have written it for him. http://www.cpreports.com/?p=917